VIR
HealthcareVir Biotechnology, Inc.
$5.79
$-0.15 (-2.53%)
Jan 5, 2026
Price History (1Y)
Analysis
Vir Biotechnology, Inc. is a healthcare company operating in the biotechnology industry, with a market capitalization of $805.53M and approximately 408 employees. The company's financial health reveals significant profitability challenges, with gross margin, operating margin, and profit margin all at 0.0%. This is accompanied by substantial net losses and negative EBITDA, free cash flow, and return on equity (49.1% loss). The balance sheet shows a moderate debt-to-equity ratio of 12.58 and a significant amount of cash ($506.51M) offsetting the relatively modest debt ($100.17M). The valuation context for Vir Biotechnology is marked by negative P/E (-2.01), EV/EBITDA (-0.82), and substantial price to sales (47.78). Revenue growth has been declining at a rate of 89.9% year-over-year, while earnings growth data is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $805.53M
- P/E Ratio
- N/A
- 52-Week High
- $14.45
- 52-Week Low
- $4.16
- Avg Volume
- 1.67M
- Beta
- 1.39
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 408